# KarMMa-4 (NCT04196491)

> A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04196491
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: bb2121; Fludarabine; Cyclophosphamide; Lenalidomide
- Enrollment: 13
- Primary outcome: Dose-limiting toxicity (DLT) rates
- Primary outcome: Adverse Events (AEs)

## Commentary we found

- YouTube: 5
- Podcasts: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=karmma-4-nct04196491

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04196491", "email": "<work email>"}; the inbox owner confirms by the emailed link.